Curis Lifesciences

CURIS

Q: How strong is Curis Lifesciences balance sheet?

Balance sheet of Curis Lifesciences is strong.But short term working capital might become an issue for this company.

Q: Is the debt of Curis Lifesciences increasing or decreasing?

The net debt of Curis Lifesciences is decreasing.Latest net debt of Curis Lifesciences is ₹14.8 Crs as of Sep-25.This is less than Mar-25 when it was ₹15.29 Crs.

Q: Is Curis Lifesciences stock expensive?

Curis Lifesciences is not expensive.Latest PE of Curis Lifesciences is 11.91, while 3 year average PE is 14.92. Also latest EV/EBITDA of Curis Lifesciences is 0 while 3yr average is 10.53.

Price

Nano Cap

₹75 Cr.

New to Zerodha? Sign-up for free.

Curis Lifesciences specializes in manufacturing pharmaceutical products like tablets, capsules, and oral liquids. It operates on loan license, contract manufacturing, and direct export/own brand mark… More

Curis Lifesciences specializes in manufacturing pharmaceutical products like tablets, capsules, and… More

Low

83.60

52W Range

High

148

12.35

Sector PE

26.38

P/B

Div.Yield

ROE

37.62%

EBIDTA

ROCE

37.61

EPS

New to Zerodha? Sign-up for free.

Get instant stock alerts

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

Coming soon

Summary
Profit & Loss
Balance sheet
Cashflow

Yearly | Quarterly

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

CURIS
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

CURIS
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

This data is currently unavailable for this company.

Events:

Quarterly Results

Announcement Date

Dec 04, 2025

More Nano Cap Ideas

See similar 'Nano' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does Curis Lifesciences do?

Curis Lifesciences is engaged in the pharma manufacturing. It specializes in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, Oral Liquid, etc. It undertakes manufacturing activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. It operates in global as well as domestic markets.

Who are the competitors of Curis Lifesciences?

Curis Lifesciences major competitors are Sotac Pharmaceutical, Lincoln Pharma. Market Cap of Curis Lifesciences is ₹73 Crs. While the median market cap of its peers are ₹671 Crs.

Is Curis Lifesciences financially stable compared to its competitors?

Curis Lifesciences seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Does Curis Lifesciences pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Curis Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Curis Lifesciences allocated its funds?

Companies resources are allocated to majorly unproductive assets like Inventory

How strong is Curis Lifesciences balance sheet?

Balance sheet of Curis Lifesciences is strong. But short term working capital might become an issue for this company.

Is the profitablity of Curis Lifesciences improving?

Yes, profit is increasing. The profit of Curis Lifesciences is ₹6.41 Crs for TTM, ₹6.11 Crs for Mar 2025 and ₹4.87 Crs for Mar 2024.

Is the debt of Curis Lifesciences increasing or decreasing?

The net debt of Curis Lifesciences is decreasing. Latest net debt of Curis Lifesciences is ₹14.8 Crs as of Sep-25. This is less than Mar-25 when it was ₹15.29 Crs.

Is Curis Lifesciences stock expensive?

Curis Lifesciences is not expensive. Latest PE of Curis Lifesciences is 11.91, while 3 year average PE is 14.92. Also latest EV/EBITDA of Curis Lifesciences is 0 while 3yr average is 10.53.

Has the share price of Curis Lifesciences grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about Curis Lifesciences?

There is Insufficient data to gauge this.

Are mutual funds buying/selling Curis Lifesciences?

There is Insufficient data to gauge this.

CURIS

Share Price

Financials

Summary

Profit & Loss

Balance sheet

Cashflow

Revenue mix

Product wise

Location wise

Shareholdings

Peers

Forensics

Recent events

News

Corporate Actions

Events:

Quarterly Results

More Nano Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Curis Lifesciences do?

Who are the competitors of Curis Lifesciences?

Is Curis Lifesciences financially stable compared to its competitors?

Does Curis Lifesciences pay decent dividends?

How has Curis Lifesciences allocated its funds?

How strong is Curis Lifesciences balance sheet?

Is the profitablity of Curis Lifesciences improving?

Is the debt of Curis Lifesciences increasing or decreasing?

Is Curis Lifesciences stock expensive?

Has the share price of Curis Lifesciences grown faster than its competition?

Is the promoter bullish about Curis Lifesciences?

Are mutual funds buying/selling Curis Lifesciences?